# Retatrutide and cancer: what the warning and the studies say

Source: https://pepvault.app/guides/retatrutide-and-cancer

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Retatrutide and cancer: what the warning and the studies say

Reviewed November 2026 21 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Retatrutide and cancer: where the GLP-1 thyroid warning comes from, who the trials left out, the cancers they counted, and what studies of the class found.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 21
- **Questions:** 9
- **Compounds:** 3

## The short answer

No study shows retatrutide causes cancer in people. It is investigational, so it has no label yet. The thyroid cancer warning on approved GLP-1 drugs comes from tumours in rats, and every retatrutide phase 3 trial left out people with a personal or family history of medullary thyroid cancer or MEN 2. Human studies of the class disagree on thyroid cancer and show no rise in most others.

- The boxed warning on Zepbound and Wegovy rests on thyroid C-cell tumours in rats and mice; the labels say the human relevance has not been determined.
- Rodent thyroid C-cells carry the GLP-1 receptor; human and monkey C-cells carry little, and 20 months of liraglutide gave monkeys no C-cell growth.
- The two phase 2 retatrutide trials posted three serious cancer events among 457 people on the drug, none of them thyroid, and none among 115 on placebo.
- For the drug class, a Scandinavian cohort of 145,410 users found no rise in thyroid cancer; a French study and two trial meta-analyses found one.

Every number checked at its primary source · Nov 20, 2026 · [21 sources](https://pepvault.app/guides/retatrutide-and-cancer#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Drug labels and rodent and monkey studies for the thyroid warning; registry records of Eli Lilly's retatrutide trials; observational cohort studies and meta-analyses of randomised trials of the approved GLP-1 drugs; one mouse study of retatrutide and tumours.

## Does retatrutide cause cancer?

Nothing so far shows that it does, and the most striking cancer result on retatrutide points the other way, in mice. In a 2025 study, mice that lost weight on retatrutide grew pancreatic tumours 14 times smaller than untreated mice, against 4 times smaller on semaglutide, and lung tumours 17 times smaller[19](https://pepvault.app/guides/retatrutide-and-cancer#source-19). That is an animal result; no trial has tested retatrutide against cancer in people.

The worry people search for is the thyroid cancer warning printed on every approved GLP-1 weight-loss drug. Retatrutide, a weekly shot that switches on the GLP-1, GIP and glucagon receptors at once (a triple agonist, pepvault.app/glossary/dual-and-triple-agonists), has no label yet, because no regulator anywhere has approved it[20](https://pepvault.app/guides/retatrutide-and-cancer#source-20). The broader safety record, from pancreatitis to heart events, is in the guide is retatrutide safe.

<!--promo-->

PepVault's side-effect log keeps each symptom with its date, compound, severity and a note, and the doctor's report puts them beside your logged doses in one document for your clinician. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-retatrutide-and-cancer-inline&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault's side-effect log keeps each symptom with its date, compound, severity and a note, and the doctor's report puts them beside your logged doses in one document for your clinician.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What does the thyroid cancer warning on GLP-1 drugs say?

It is a boxed warning (pepvault.app/glossary/boxed-warning), the FDA's strongest label warning, about one rare cancer. Medullary thyroid carcinoma (MTC) starts in the thyroid's C-cells, which make the hormone calcitonin. Zepbound's label says tirzepatide causes C-cell tumours in rats that rise with dose and treatment length, and that it is unknown whether it does so in humans, because the human relevance has not been determined[1](https://pepvault.app/guides/retatrutide-and-cancer#source-1). Wegovy's label says the same of semaglutide in mice and rats[2](https://pepvault.app/guides/retatrutide-and-cancer#source-2).

| What the labels say | Zepbound (tirzepatide) | Wegovy (semaglutide) |
| --- | --- | --- |
| Animals with C-cell tumours | Rats, in a 2-year study; a 6-month study in transgenic mice found none | Mice and rats, over a lifetime |
| Exposure at which tumours rose | Every dose tested, 0.1 to 1 times the human exposure at 15 mg a week | Clinically relevant exposures in both species |
| Who must not use it | A personal or family history of MTC, or MEN 2 | The same |
| Human reports | Human relevance not determined | MTC cases reported after approval in people on liraglutide, too few to show or rule out a cause |

MEN 2 (multiple endocrine neoplasia type 2) is an inherited condition that makes MTC likely, so both labels make it a contraindication (pepvault.app/glossary/contraindication), a reason not to use the drug at all[1](https://pepvault.app/guides/retatrutide-and-cancer#source-1) [2](https://pepvault.app/guides/retatrutide-and-cancer#source-2). Both also say routine calcitonin tests or thyroid ultrasounds are of uncertain value for catching MTC early and can lead to unnecessary procedures, because the test is not specific and thyroid disease is common[1](https://pepvault.app/guides/retatrutide-and-cancer#source-1) [2](https://pepvault.app/guides/retatrutide-and-cancer#source-2).

## Why do rats get thyroid tumours on GLP-1 drugs?

Because rat C-cells are built to answer GLP-1, and human ones mostly are not. Novo Nordisk's scientists traced the rodent tumours in 2010: rat and mouse C-cells carry the GLP-1 receptor, and the drugs made them release calcitonin and then multiply, more in rats than in mice. Human and cynomolgus monkey C-cells had little of the receptor, and the drugs set off no calcitonin release in primates[3](https://pepvault.app/guides/retatrutide-and-cancer#source-3).

In monkeys, 20 months of liraglutide at more than 60 times the human exposure caused no C-cell growth[3](https://pepvault.app/guides/retatrutide-and-cancer#source-3). In people on liraglutide for two years, calcitonin stayed at the low end of normal, with no more people crossing the 20 pg/ml cut-off than on comparison treatment[3](https://pepvault.app/guides/retatrutide-and-cancer#source-3). The authors still called the long-term effect on the human thyroid unknown, which is why the warning stays on the label[3](https://pepvault.app/guides/retatrutide-and-cancer#source-3).

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [GLP-1s and the heart: heart rate, blood pressure and the SELECT trial](https://pepvault.app/guides/glp-1s-and-the-heart)
- [Do GLP-1s cause cancer? The thyroid warning and what the studies show](https://pepvault.app/guides/do-glp-1s-cause-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Contraindication](https://pepvault.app/glossary/contraindication)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)

## Who did the retatrutide trials leave out because of cancer?

The five phase 3 trials below and the phase 2 obesity trial all turned away anyone with a personal or family history of MTC or MEN 2, the group the approved labels rule out[4](https://pepvault.app/guides/retatrutide-and-cancer#source-4) [5](https://pepvault.app/guides/retatrutide-and-cancer#source-5) [6](https://pepvault.app/guides/retatrutide-and-cancer#source-6) [7](https://pepvault.app/guides/retatrutide-and-cancer#source-7) [8](https://pepvault.app/guides/retatrutide-and-cancer#source-8) [9](https://pepvault.app/guides/retatrutide-and-cancer#source-9). From each trial's ClinicalTrials.gov record, all sponsored by Eli Lilly:

| Trial | People | MTC or MEN 2 history excluded | Other cancer excluded |
| --- | --- | --- | --- |
| Phase 2, obesity | 338 | Yes (first-degree relatives) | Active cancer in the last 5 years |
| Phase 2, type 2 diabetes | 281 | Not in the registry's list | Active or untreated cancer |
| TRIUMPH-1, obesity | 2,335 | Yes | Not in the registry's list |
| TRIUMPH-2, obesity and diabetes | 1,152 | Yes | Not in the registry's list |
| TRIUMPH-3, obesity and heart disease | 1,946 | Yes | Not in the registry's list |
| TRANSCEND-T2D-1, diabetes | 537 | Yes | Active or untreated cancer, or remission under 5 years |
| TRIUMPH-Outcomes, heart and kidney (running) | About 10,000 | Yes | Not in the registry's list |

So the results describe people without that thyroid history, and say nothing about anyone with it. Whether retatrutide's label carries the same boxed warning is the FDA's call at review. Retatrutide's own rodent cancer studies are not public, so whether rats on it grow the same tumours is not known outside Lilly.

## Did anyone in the retatrutide trials get cancer?

Three people, none with thyroid cancer. The two phase 2 trials are the only ones with results posted to the registry, which lists every serious adverse event, one that puts someone in hospital or threatens life, whatever its cause[9](https://pepvault.app/guides/retatrutide-and-cancer#source-9) [10](https://pepvault.app/guides/retatrutide-and-cancer#source-10):

| Serious event | Obesity trial: retatrutide (267) | Obesity trial: placebo (70) | Diabetes trial: retatrutide (190) | Diabetes trial: placebo (45) |
| --- | --- | --- | --- | --- |
| Kidney cancer (clear cell renal cell carcinoma) | 1 | 0 | 0 | 0 |
| Melanoma | 0 | 0 | 1 | 0 |
| Basal cell skin cancer | 0 | 0 | 1 | 0 |
| Calcitonin rise reported as serious | 0 | 1 | 0 | 0 |
| Thyroid cancer | 0 | 0 | 0 | 0 |

The kidney cancer came on 4 mg, and the melanoma and skin cancer both in one 4 mg group of 24 people[9](https://pepvault.app/guides/retatrutide-and-cancer#source-9) [10](https://pepvault.app/guides/retatrutide-and-cancer#source-10). Groups this small, followed for 52 weeks and 280 days, give no rate[9](https://pepvault.app/guides/retatrutide-and-cancer#source-9) [10](https://pepvault.app/guides/retatrutide-and-cancer#source-10). No phase 3 trial has posted results yet[4](https://pepvault.app/guides/retatrutide-and-cancer#source-4) [5](https://pepvault.app/guides/retatrutide-and-cancer#source-5) [6](https://pepvault.app/guides/retatrutide-and-cancer#source-6) [7](https://pepvault.app/guides/retatrutide-and-cancer#source-7), and the TRIUMPH-1 abstract gives no cancer counts[11](https://pepvault.app/guides/retatrutide-and-cancer#source-11).

## Do GLP-1 drugs raise thyroid cancer risk in people?

The studies split, and the absolute numbers are small either way. Observational studies (pepvault.app/glossary/observational-study) follow people who were prescribed a drug, so other differences between groups can creep in. Meta-analyses pool randomised trials, where the drug was assigned by chance, but trial cancers are few. None of these studies included retatrutide.

| Study | Who | Thyroid cancer result (95% CI) |
| --- | --- | --- |
| France, national health data, 2023[12](https://pepvault.app/guides/retatrutide-and-cancer#source-12) | 2,562 people with thyroid cancer and 45,184 matched controls, all with type 2 diabetes | 1 to 3 years of GLP-1 use: 1.58 times the risk (1.27 to 1.95); MTC 1.78 (1.04 to 3.05) |
| Denmark, Norway and Sweden, 2024[13](https://pepvault.app/guides/retatrutide-and-cancer#source-13) | 145,410 GLP-1 users against 291,667 users of DPP-4 inhibitors, another diabetes drug, followed 3.9 years on average | 0.93 (0.66 to 1.31), no rise; MTC 1.19 (0.37 to 3.86) |
| Meta-analysis of 64 trials, 2024[14](https://pepvault.app/guides/retatrutide-and-cancer#source-14) | Trials of 52 weeks or longer | 1.52 times the odds (1.01 to 2.29); one extra case per 1,349 people treated for 5 years |
| Meta-analysis of 50 trials, 2025[15](https://pepvault.app/guides/retatrutide-and-cancer#source-15) | Diabetes and obesity trials of 52 weeks or longer | 1.55 (1.05 to 2.27) |

A result above 1 means more cancer on the drug; a range that crosses 1 (pepvault.app/glossary/confidence-interval) means no clear difference. In the Scandinavian study, thyroid cancer came at 1.33 cases per 10,000 person-years on GLP-1 drugs and 1.46 on DPP-4 inhibitors, and its upper limit rules out more than a 31% rise[13](https://pepvault.app/guides/retatrutide-and-cancer#source-13). The 2024 meta-analysis found no clear rise for MTC alone, 1.44 (0.23 to 9.16), and its main finding would flip with one case moved (a fragility index of 1)[14](https://pepvault.app/guides/retatrutide-and-cancer#source-14). The 2025 authors put a short-term rise in colorectal cancer down to extra tests prompted by the drugs' gut side effects[15](https://pepvault.app/guides/retatrutide-and-cancer#source-15), and more check-ups can turn up small thyroid cancers the same way.

## Do GLP-1 drugs change the risk of other cancers?

Across most cancers, no rise has turned up, and several fell. The 2025 meta-analysis of 50 trials found no difference in overall cancer, an odds ratio of 1.05 (0.98 to 1.13), and fewer uterine cancers in the obesity trials[15](https://pepvault.app/guides/retatrutide-and-cancer#source-15). Pancreatic cancer, an early worry for the class, did not rise over 7 years in an Israeli study of 543,595 adults with diabetes, against basal insulin[17](https://pepvault.app/guides/retatrutide-and-cancer#source-17).

The largest study, US health records of 1,651,452 people with type 2 diabetes, compared GLP-1 drugs with insulin and found lower risk in 10 of 13 obesity-linked cancers, among them pancreatic (hazard ratio 0.41), liver (0.47) and colorectal cancer (0.54), and no lower risk of thyroid or postmenopausal breast cancer[16](https://pepvault.app/guides/retatrutide-and-cancer#source-16). Against metformin, the GLP-1 drugs lowered none of the 13 and came with more kidney cancer, 1.54 (1.27 to 1.87)[16](https://pepvault.app/guides/retatrutide-and-cancer#source-16). People prescribed insulin tend to have longer, harder diabetes, which is part of why the comparator changes the answer.

## Can losing weight lower cancer risk?

Excess body fat causes at least 13 cancers, according to the International Agency for Research on Cancer, the WHO's cancer agency, after a 2016 review of more than 1,000 studies: cancers of the oesophagus, top of the stomach, colon and rectum, liver, gallbladder, pancreas, postmenopausal breast, womb, ovary, kidney and thyroid, plus multiple myeloma and meningioma[18](https://pepvault.app/guides/retatrutide-and-cancer#source-18).

Thyroid cancer is on that list, so people who start a weight-loss drug carry a raised thyroid cancer risk before the first dose. The mouse study at the top found that retatrutide's protection against tumours held even after the mice stopped the drug and regained weight[19](https://pepvault.app/guides/retatrutide-and-cancer#source-19). Species note: those were mouse cancer models; whether drug-driven weight loss lowers cancer in people, no trial has yet shown.

## What is still unknown about retatrutide and cancer?

- **Long-term cancer counts.** The phase 3 trials ran 40 to 80 weeks, with an extension to 104 weeks in TRIUMPH-1[7](https://pepvault.app/guides/retatrutide-and-cancer#source-7) [11](https://pepvault.app/guides/retatrutide-and-cancer#source-11) [21](https://pepvault.app/guides/retatrutide-and-cancer#source-21). Cancers take years; TRIUMPH-Outcomes, about 10,000 adults, runs into 2029[8](https://pepvault.app/guides/retatrutide-and-cancer#source-8).
- **Whether the glucagon arm changes anything.** No approved drug switches on the glucagon receptor this way, so the class studies cover GLP-1 drugs and tirzepatide, not a triple agonist.

Who can take a GLP-1 drug with a thyroid history, or after cancer, is the prescriber's decision, made against the label; for retatrutide, which has no label, it is a trial investigator's. Lilly says anyone selling retatrutide to consumers is breaking the law[20](https://pepvault.app/guides/retatrutide-and-cancer#source-20); the legal side is at pepvault.app/peptides/retatrutide/legal-status.

**When to get help** The labels name the thyroid signs to report: a lump or swelling in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away; any of these is a reason to see a doctor[1](https://pepvault.app/guides/retatrutide-and-cancer#source-1) [2](https://pepvault.app/guides/retatrutide-and-cancer#source-2).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information: boxed warning, 5.1 risk of thyroid C-cell tumours, 13.1 carcinogenesis. Version 40, effective August 28, 2026 (DailyMed; read through openFDA). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
2. Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information: boxed warning, 5.1 risk of thyroid C-cell tumours, 13.1 carcinogenesis (DailyMed; read through openFDA). [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564)
3. Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010. [PubMed 20203154](https://pubmed.ncbi.nlm.nih.gov/20203154/)
4. ClinicalTrials.gov NCT05929066 (TRIUMPH-1). A study of retatrutide (LY3437943) in participants who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05929066)
5. ClinicalTrials.gov NCT05929079 (TRIUMPH-2). A study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05929079)
6. ClinicalTrials.gov NCT05882045 (TRIUMPH-3). A study of retatrutide in participants with obesity and cardiovascular disease (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05882045)
7. ClinicalTrials.gov NCT06354660 (TRANSCEND-T2D-1). Retatrutide compared with placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone (phase 3; sponsor Eli Lilly and Company). Eligibility criteria. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06354660)
8. ClinicalTrials.gov NCT06383390 (TRIUMPH-Outcomes). The effect of retatrutide once weekly on cardiovascular and kidney outcomes in adults living with obesity (phase 3; sponsor Eli Lilly and Company). Eligibility criteria and status. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383390)
9. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or overweight (phase 2; sponsor Eli Lilly and Company). Eligibility and results record: serious adverse events. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881760)
10. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Eligibility and results record: serious adverse events. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867785)
11. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
12. Bezin J et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023. [PubMed 36356111](https://pubmed.ncbi.nlm.nih.gov/36356111/)
13. Pasternak B et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024. [PubMed 38683947](https://pubmed.ncbi.nlm.nih.gov/38683947/)
14. Silverii GA et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024. [PubMed 38018310](https://pubmed.ncbi.nlm.nih.gov/38018310/)
15. Silverii GA et al. GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2025. [PubMed 40437949](https://pubmed.ncbi.nlm.nih.gov/40437949/)
16. Wang L et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024. [PubMed 38967919](https://pubmed.ncbi.nlm.nih.gov/38967919/)
17. Dankner R et al. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024. [PubMed 38175642](https://pubmed.ncbi.nlm.nih.gov/38175642/)
18. Lauby-Secretan B et al.; IARC Handbook Working Group. Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med. 2016. [PubMed 27557308](https://pubmed.ncbi.nlm.nih.gov/27557308/)
19. Marathe SJ et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025. [PubMed 40094000](https://pubmed.ncbi.nlm.nih.gov/40094000/)
20. Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, Oct 28, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html)
21. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

How much lean mass people lost on retatrutide in its DXA scan study, dose by dose, how it compares with tirzepatide and semaglutide, and what phase 3 left out.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)

  Is retatrutide safe? What its trials counted of pancreatitis, gallbladder and heart events, low blood sugar and deaths, who was left out, and what is unknown.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)

  Retatrutide side effects by dose in its trials: nausea, diarrhoea, skin tingling and heart rate, when they show up, how many stopped, and what helps.

  Read the guide
- Guide · GLP-1s

  ### [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)

  Retatrutide isn't approved yet. Lilly plans to file with the FDA in early 2027. The review clock, the phase 3 dates and the court case, as of November 2026.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)

  Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

  Read the guide
- Guide · GLP-1s

  ### [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)

  Retatrutide in women: the share of women and ages in each trial, why Lilly capped women, how much more weight women lost, and why pregnancy was excluded.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)
- [Constipation on Ozempic, Mounjaro or Zepbound: how common, and what helps](https://pepvault.app/guides/constipation-on-a-glp-1)
- [Nausea on Ozempic, Wegovy, Mounjaro or Zepbound: when it peaks and what helps](https://pepvault.app/guides/nausea-on-a-glp-1)
- [Headaches on a GLP-1: how common they were in the trials](https://pepvault.app/guides/headaches-on-a-glp-1)
- [Sulfur burps on Ozempic or Mounjaro: why they happen](https://pepvault.app/guides/sulfur-burps-on-a-glp-1)
- [GLP-1s and the gallbladder: gallstones, and taking one without a gallbladder](https://pepvault.app/guides/glp-1s-and-the-gallbladder)
- [GLP-1s and the heart: heart rate, blood pressure and the SELECT trial](https://pepvault.app/guides/glp-1s-and-the-heart)
- [Do GLP-1s cause cancer? The thyroid warning and what the studies show](https://pepvault.app/guides/do-glp-1s-cause-cancer)
- [Retatrutide and muscle loss: what the studies measured](https://pepvault.app/guides/retatrutide-and-muscle)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [Contraindication](https://pepvault.app/glossary/contraindication)
- [Boxed warning](https://pepvault.app/glossary/boxed-warning)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
